{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:20:19Z","timestamp":1795029619562,"version":"4.10.2"},"reference-count":115,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2025,7,24]]},"DOI":"10.1080\/1750743x.2025.2545170","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T14:38:36Z","timestamp":1754923116000},"page":"767-782","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Evaluating rilzabrutinib in the treatment of immune thrombocytopenia"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-8810","authenticated-orcid":false,"given":"David J.","family":"Kuter","sequence":"first","affiliation":[{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-6165","authenticated-orcid":false,"given":"Waleed","family":"Ghanima","sequence":"additional","affiliation":[{"name":"University of Oslo","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1810479"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01247.x"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.07.015"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.02911.x"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07615.x"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02147.x"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21616"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19495"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14446"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24463"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20992"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26036"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26045"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.018390"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep16020021"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6020016"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-021-00797-w"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3770"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-015-8686-5"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2019.11.031"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13385"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2672"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03527-1"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-852491"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12592"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-1-200701020-00006"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-393975"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61495-1"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16672"},{"key":"e_1_3_7_33_1","volume-title":"Promacta\u00ae (eltrombopag) prescribing information","year":"2023","unstructured":"Promacta\u00ae (eltrombopag) prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2023 Oct."},{"key":"e_1_3_7_34_1","volume-title":"Nplate\u00ae (romiplostim) prescribing information","year":"2022","unstructured":"Nplate\u00ae (romiplostim) prescribing information. Thousand Oaks (CA): Amgen, Inc.; 2022 Feb."},{"key":"e_1_3_7_35_1","volume-title":"Doptelet\u00ae (avatrombopag) prescribing information","year":"2024","unstructured":"Doptelet\u00ae (avatrombopag) prescribing information. Stockholm, Sweden: Sobi, Inc.; 2024 Jul."},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-514398"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.21037\/aob-21-23"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13827"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-748707"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60402-5"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60203-2"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.212845"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054626"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000966"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15573"},{"key":"e_1_3_7_46_1","volume-title":"Tavalisse\u00ae (fostamatinib) prescribing information","year":"2020","unstructured":"Tavalisse\u00ae (fostamatinib) prescribing information. South San Francisco (CA): Rigel Pharmaceuticals; 2020 Nov."},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25125"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000001303"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-742353"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1168"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.9.6.722"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0513307"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90667-F"},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/361226a0"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000412"},{"key":"e_1_3_7_56_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01454"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2016.1152888"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01353-w"},{"key":"e_1_3_7_59_1","volume-title":"Imbruvica\u00ae (ibrutinib) prescribing information","year":"2024","unstructured":"Imbruvica\u00ae (ibrutinib) prescribing information. South San Francisco (CA): Pharmacyclics LLC and Horsham, PA: Janssen Biotech; 2024 Dec."},{"key":"e_1_3_7_60_1","volume-title":"Calquence\u00ae (acalabrutinib) prescribing information","year":"2025","unstructured":"Calquence\u00ae (acalabrutinib) prescribing information. Cambridge, (UK): AstaZeneca; 2025 Jan."},{"key":"e_1_3_7_61_1","volume-title":"Brukinsa\u00ae(zanubrutinib) prescribing information","year":"2025","unstructured":"Brukinsa\u00ae(zanubrutinib) prescribing information. Cambridge (MA): BeiGene; 2025 Jan."},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13651"},{"key":"e_1_3_7_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.273"},{"key":"e_1_3_7_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.5"},{"key":"e_1_3_7_65_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.126672"},{"key":"e_1_3_7_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583294"},{"key":"e_1_3_7_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2021.1980313"},{"key":"e_1_3_7_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_3_7_69_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0463"},{"key":"e_1_3_7_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa145"},{"key":"e_1_3_7_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140172"},{"key":"e_1_3_7_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"e_1_3_7_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00562"},{"key":"e_1_3_7_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0670"},{"key":"e_1_3_7_75_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01170"},{"key":"e_1_3_7_76_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001130"},{"key":"e_1_3_7_77_1","unstructured":"National center for biotechnology information. PubChem compound summary for CID 73388818 rilzabrutinib. [cited 2025 Feb 5]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Rilzabrutinib"},{"issue":"5","key":"e_1_3_7_78_1","first-page":"1663","article-title":"Rapid tyrosine phosphorylation and activation of Bruton\u2019s tyrosine\/Tec kinases in platelets induced by collagen binding or CD32 cross-linking","volume":"95","author":"Oda A","year":"2000","unstructured":"Oda A, Ikeda Y, Ochs HD, et al. Rapid tyrosine phosphorylation and activation of Bruton\u2019s tyrosine\/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. Blood. 2000;95(5):1663\u20131670.","journal-title":"Blood"},{"key":"e_1_3_7_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012713"},{"key":"e_1_3_7_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12878"},{"key":"e_1_3_7_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200182"},{"key":"e_1_3_7_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13351"},{"key":"e_1_3_7_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13271"},{"key":"e_1_3_7_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110297"},{"key":"e_1_3_7_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012044"},{"key":"e_1_3_7_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27539"},{"key":"e_1_3_7_87_1","volume-title":"International Society on Thrombosis and Haemostasis Congress","author":"Kuter DJ","unstructured":"Kuter DJ, Bird R, Jansen AJG, et al. Pooled analysis of the efficacy and safety of oral Bruton tyrosine kinase inhibitor rilzabrutinib in patients with previously treated immune thrombocytopenia: phase 2 study. International Society on Thrombosis and Haemostasis Congress; 2024 Jun 22\u201326; Bangkok, Thailand."},{"key":"e_1_3_7_88_1","volume-title":"Presented at ASH 2024","author":"Kuter DJ","unstructured":"Kuter DJ, Ghanima W, Cooper N, et al. Efficacy and safety of oral Bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib in adults with previously treated immune thrombocytopenia (ITP): a phase 3, placebo-controlled, parallel-group, multicenter study (LUNA 3). Presented at ASH 2024."},{"key":"e_1_3_7_89_1","volume-title":"Presented at: European Hematology Association annual meeting","author":"Cooper N","year":"2024","unstructured":"Cooper N, Jansen A, Tarantino M, et al. Long-term safety and efficacy of rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with immune thrombocytopenia (ITP): integrated phase 2 part a and part B. In: Presented at: European Hematology Association annual meeting; Madrid, Spain; 2024 Jun 13\u201316."},{"key":"e_1_3_7_90_1","first-page":"4238","article-title":"Clinical predictors of response to oral Bruton tyrosine kinase inhibitor rilzabrutinib in previously treated patients with immune thrombocytopenia: pooled analysis of phase 2 study","volume":"8","author":"Ghanima W","year":"2024","unstructured":"Ghanima W, Cooper N, Khan U, et al. Clinical predictors of response to oral Bruton tyrosine kinase inhibitor rilzabrutinib in previously treated patients with immune thrombocytopenia: pooled analysis of phase 2 study. HemaSphere. 2024;8:4238\u20134239 (abstract P2236).","journal-title":"HemaSphere"},{"key":"e_1_3_7_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027336"},{"key":"e_1_3_7_92_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231205431"},{"key":"e_1_3_7_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200279"},{"key":"e_1_3_7_94_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802634119"},{"key":"e_1_3_7_95_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000749"},{"key":"e_1_3_7_96_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051103"},{"key":"e_1_3_7_97_1","unstructured":"Sanofi Data on File."},{"key":"e_1_3_7_98_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000844056.11024.40"},{"key":"e_1_3_7_99_1","doi-asserted-by":"publisher","DOI":"10.1159\/000439002"},{"key":"e_1_3_7_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003808"},{"key":"e_1_3_7_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200325"},{"key":"e_1_3_7_102_1","unstructured":"Clinicaltrials.gov. Efficacy safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia (wAIHA). [cited 2025 Mar 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05002777"},{"key":"e_1_3_7_103_1","volume-title":"Presented at the European Hematology Association Congress","author":"Cooper N","unstructured":"Cooper N, Kuter D, Fattizzo B, et al. Impact of rilzabrutinib on biomarkers of inflammation and complement factors in warm autoimmune hemolytic anemia (wAIHA): results from the phase 2 study. Presented at the European Hematology Association Congress; 2025 Jun 12\u201315; Milan, Italy."},{"key":"e_1_3_7_104_1","volume-title":"Presentated at the European Hematology Association Congress","author":"Fattizzo B","unstructured":"Fattizzo B, Frederiksen H, Cooper N, et al. Long-term efficacy and safety study of rilzabrutinib, oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune hemolytic anemia (wAIHA): LUMINA phase 2B part B. Presentated at the European Hematology Association Congress; 2025 Jun 12\u201315; Milan, Italy."},{"key":"e_1_3_7_105_1","unstructured":"Clinicaltrials.gov. Proof of concept study of rilzabrutinib in adult participants with moderate-to-severe asthma. [cited 2025 Mar 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05104892"},{"key":"e_1_3_7_106_1","first-page":"A7002","article-title":"Efficacy and safety of rilzabrutinib - a novel oral treatment in asthma: results from a double blind placebo controlled phase 2 study","volume":"209","author":"Laidlaw TM","year":"2024","unstructured":"Laidlaw TM, Maspero JF, Pavord ID, et al. Efficacy and safety of rilzabrutinib - a novel oral treatment in asthma: results from a double blind placebo controlled phase 2 study. Am J Respir Crit Care Med. 2024;209:A7002.","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_7_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.893"},{"key":"e_1_3_7_108_1","unstructured":"Clinicaltrials.gov. Rilzabrutinib for the treatment of chronic spontaneous urticaria in patients who remain symptomatic despite the use of H1 antihistamine (RILECSU). [cited 2025 Mar 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05107115"},{"key":"e_1_3_7_109_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.407"},{"key":"e_1_3_7_110_1","unstructured":"Clinicaltrials.gov. Open label two-arm study to evaluate rilzabrutinib in IgG4-related disease participants. [cited 2025 Mar 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04520451"},{"key":"e_1_3_7_111_1","volume-title":"Presented at: European Academy of Dermatology and Venereology Symposium (EADV-S 2024)","author":"Kircik L","year":"2024","unstructured":"Kircik L, Tsianakas A, Valenzuela F, et al. Efficacy and safety of rilzabrutinib in patients with moderate to severe atopic dermatitis: a proof-of-concept phase 2 clinical trial. In: Presented at: European Academy of Dermatology and Venereology Symposium (EADV-S 2024); St. Julian\u2019s, Malta; 2024 May 16\u201318."},{"key":"e_1_3_7_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.02.023"},{"key":"e_1_3_7_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20431"},{"key":"e_1_3_7_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18318"},{"key":"e_1_3_7_115_1","unstructured":"FDA grants fast track designation to rilzabrutinib for treatment of immune thrombocytopenia. [cited 2025 Mar 5]. Available from: https:\/\/www.targetedonc.com\/view\/fda-grants-fast-track-designation-to-rilzabrutinib-for-treatment-of-immune-thrombocytopenia"},{"key":"e_1_3_7_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20045"},{"key":"e_1_3_7_117_1","unstructured":"Clinicaltrials.gov. Study to evaluate the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia (ITP) who failed first-line treatment (LUNA 4). [cited 2025 Jun 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07007962"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1750743X.2025.2545170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T08:29:33Z","timestamp":1766996973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1750743X.2025.2545170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":115,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,7,24]]}},"alternative-id":["10.1080\/1750743X.2025.2545170"],"URL":"https:\/\/doi.org\/10.1080\/1750743x.2025.2545170","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}